PLAU Recombinant Monoclonal Antibody

說明書

中文名稱：

PLAU重組抗體
貨號(hào)：

CSB-RA963043A0HU
規(guī)格：

￥1320
圖片：
IHC image of CSB-RA963043A0HU diluted at 1:100 and staining in paraffin-embedded human prostate cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA963043A0HU重組單克隆抗體是針對(duì)PLAU（尿激酶型纖溶酶原激活劑）研發(fā)的高特異性試劑，靶向參與細(xì)胞外基質(zhì)降解及腫瘤侵襲轉(zhuǎn)移的關(guān)鍵蛋白酶。該抗體經(jīng)ELISA和免疫組化（IHC）驗(yàn)證，在IHC實(shí)驗(yàn)中可清晰顯示石蠟包埋組織中PLAU蛋白的定位分布，推薦使用稀釋比為1:50至1:200。其重組單克隆特性確保了批間一致性和低交叉反應(yīng)性，適用于腫瘤微環(huán)境、細(xì)胞遷移及血管生成等機(jī)制的體外研究。實(shí)驗(yàn)數(shù)據(jù)顯示，該抗體在多種組織樣本中表現(xiàn)出良好的抗原識(shí)別能力，尤其適合用于癌癥生物學(xué)領(lǐng)域的功能研究，例如腫瘤侵襲性評(píng)估或藥物干預(yù)效果分析。本產(chǎn)品嚴(yán)格限定于科學(xué)研究用途，可為探索PLAU在病理生理過程中的調(diào)控機(jī)制提供可靠工具。
Uniprot No.：

P00749
基因名：

PLAU
別名：

Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B], PLAU
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human Urokinase
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

10E5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
基因功能參考文獻(xiàn)：
1. The combination of decoy receptor 3, soluble urokinase type plasminogen activator receptor, and procalcitonin improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the efficiency of sepsis diagnosis. PMID: 29760745
2. High Expressions of PLAU is associated with lung adenocarcinoma. PMID: 28454121
3. Increased expression of uPA in epidermal cells in psoriasis and in tumor cells in basal cell carcinomas suggests an important role of the uPA system for aggressively proliferating and invading cells of epidermal origin. PMID: 28429105
4. study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA and uPAR PMID: 28643742
5. Gelsolin enhances the invasive capacity of colon cancer cells via elevating intracellular superoxide (O2.-) levels by interacting with Cu/ZnSOD, and gelsolin gene expression positively correlates with urokinase plasminogen activator (uPA), an important matrix-degrading protease invovled in cancer invasion. PMID: 27391159
6. Study provides evidence that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and function of cancer-associated fibroblasts during multiple myeloma. PMID: 28340565
7. OB-Rb, RhoA/ROCK, PI3K/AKT, JAK/STAT pathways and NF-kB activation are involved in leptin-induced upA expression. PMID: 28104444
8. Results provide evidence that uPA and IGF1R directly interact with uPAR enhancing malignant potential of triple-negative breast cancer. PMID: 27502396
9. suggest that the low endogenous levels of uPA in blood are actively regulated, and that the regulatory mechanisms are disrupted in QPD in a megakaryocyte-specific manner PMID: 28301587
10. an intricate link between caveolin-1 and Src kinase-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C expression through p53 and uPA system-mediated cross-talk, is reported. PMID: 28385810
11. results show that the uPA/uPAR/LRP1 system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury PMID: 27986809
12. The present research concluded that aspirin suppressed prostate cancer cell invasion by reducing MMP-9 activity and uPA expression through decreasing of IKK-beta-mediated NF-kappaB activation, indicating that the ability of aspirin to inhibit cell invasion might be useful in the chemoprevention of metastatic prostate cancer. PMID: 28278500
13. These studies identify uPA-dependent de-repression of vegfr1 and vegfr2 gene transcription through binding to HHEX/PRH as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF and identifies a potential new target for control of pathologic angiogenesis. PMID: 27151212
14. The up-regulation of uPA mRNAs was correlated with high-risk clinicopathological features, including extrathyroid invasion, loss of cellular polarity/cohesiveness, and the BRAF(V600E) mutation. PMID: 25085839
15. Transplantation of uPA gene modified mesenchymal stem cells suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis PMID: 26877613
16. ApaL1 and Taq1 single nucleotide polymorphisms of the urokinase and VDR genes are associated with recurrent urolithiasis in a Caucasian population. PMID: 26275878
17. Resveratrol inhibited hypoxia-induced HIF-1alpha protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA and MMP2. PMID: 26707376
18. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. PMID: 26846181
19. Data suggest that enhanced levels of uPA in breast cancer modulate the mitogenic effects of EGF which helps to better understand breast cancer pathogenesis. PMID: 25641046
20. Results found high levels of uPA and uPAR exclusively in metastatic osteosarcoma (OS)cells and suggest that malignant conversion of OS cells to uPA/uPAR axis in an autocrine and paracrine fashion. PMID: 26317203
21. The morphologically normal tissue adjacent to the tumor shows the substantial expression of MMP-2 and MMP-9 and in some cases the enhanced activity of uPA and ACE, which makes an additional contribution to the increased invasive potential of tumor PMID: 26978018
22. it was found that the recombinant fusion protein uPA17-34-KPI(kunitz-type protease inhibitor ) inhibited the invasion and metastasis of ovarian tumors PMID: 26166362
23. Crystal structure of uPA bound with cyclic peptidic inhibitors. PMID: 25744057
24. u-PA is a dysregulated gene involved in the tumorigenesis, bio-pathological features and outcomes of EEC. PMID: 26033187
25. High cytoplasmic expression of uPA is associated with cells of rectal cancer and metastases of perienteric lymph nodes. PMID: 26504024
26. DIM can influence the cell migratory and invasive properties of human colorectal cancer cells and may decrease the invasive capacity of colorectal cancer through downregulation of uPA and MMP9 mediated by suppression of the transcription factor FOXM1 PMID: 25962429
27. Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA. PMID: 25979345
28. SNP P141L associated with collateral circulation in coronary artery disease PMID: 24952395
29. Taking uPA(1-43) amino acids specifically binding to uPAR as targeted part of fusion protein, and making use of antitumor activity of melittin, the recombinant fusion protein it was able to inhibit growth of ovarian tumors . PMID: 25394558
30. uPA/uPAR stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2 PMID: 25244504
31. Studied urokinase-type plasminogen activator regulation in cigarette smoke extract (CSE)-induced EMT in human small airway epithelial cell lines (HSAEpiCs)and in the small airway epithelium of COPD patients. PMID: 25706093
32. Silencing of ETV4 suppresses invasion of prostate cancer cells by inhibiting the expression of uPA/uPAR as well as (MMP)-2 and MMP-9 PMID: 25544710
33. miR-193b inhibits the expression of stathmin 1 (STMN1) and urokinase-type plasminogen activator (uPA) in Panc-1 cells. PMID: 25215905
34. Activation of uPA and MMP-3 in perifocal zone of the tumor can serve as an indexof its invasive activity. PMID: 25993872
35. These data support the hypothesis that uPA upregulation stimulated by macrophages may play an active role in the onset of osteoarthritis and in the shear-stress protection against this induction. PMID: 23597113
36. High preprocedural plasma uPA and serum CRP levels are indicative of angina recurrence after successful PTCA, and are valuable for the prognosis of restenosis. PMID: 24057344
37. Data indicate that urokinase-type plasminogen activator (uPA) activates epithelial sodium channel, gamma subunit (ENaC gamma) through catalytic activity-dependent proteolytic modification. PMID: 25555911
38. IL-17 may act as chemotropic factor for peripheral blood-Mesenchymal stem cellss by incrementing cell motility and uPA expression during inflammation development. PMID: 25433194
39. Suggest a possible protective effect of podocyte uPA/uPAR expression against interstitial fibrosis in IgA nephritis. PMID: 24648800
40. High u-PA expression is associated with metastasis in breast cancer. PMID: 24610082
41. In human coronary vascular smooth muscle, uPA induces uPAR-independent, domain-dependent smooth muscle cell proliferation through transactivation of EGFR by a plasmin-mediated, ADAM-induced, and HB-EGF-dependent process. PMID: 25082749
42. IL-33 is involved in u-PA-driven angiogenesis, a process that has been shown before to be linked to inflammation in various pathologies. PMID: 24702774
43. IL-1beta-induced urokinase plasminogen activator expression via activation of the ERK1/2 and NF-kappaB pathways, which results in invasion of gastric cancer cells. PMID: 24626561
44. Studied the relationship between uPA gene polymorphisms and clinical manifestations of idiopathic membranous nephropathy. PMID: 24822208
45. These effects were mediated by the efficient conversion of pro-uPA to active uPA and high phosphorylation levels of ERK detected in the PANC-1 cells expressing exogenous polyserase-1. PMID: 24756697
46. We found no association between allele frequency and risk of multiples sclerosis for any single nucleotide polymorphism investigated for PLAU PMID: 23897640
47. results of this study suggest that uPA decreases the removal of HDL-cholesteryl ester in the liver via suppression of the hepatic scavenger receptor class B type I (SR-BI)expression PMID: 24529115
48. Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PMID: 24340014
49. The findings provide evidence that the rs2227564 C/T SNP in the u-PA gene is associated with the development of oral tongue squamous cell carcinoma. PMID: 23621237
50. Decreasing uPA levels sensitized cancer cells to TRAIL, leading to markedly increased apoptosis. PMID: 24481457
顯示更多

收起更多
相關(guān)疾病：

Quebec platelet disorder (QPD)
亞細(xì)胞定位：

Secreted.
蛋白家族：

Peptidase S1 family
組織特異性：

Expressed in the prostate gland and prostate cancers.
數(shù)據(jù)庫鏈接：

HGNC: 9052

OMIM: 191840

KEGG: hsa:5328

STRING: 9606.ENSP00000361850

UniGene: Hs.77274

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human